Eying a potential blockbuster, Bayer has been busy making the case for its new kidney disease launch Kerendia since the med won approval last summer. Now, the company is touting a pooled dataset showing a reduction in cardio and kidney events for high-risk patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,